This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sehn, L. H. Articles by Soiffer, R. J. Search for Related Content PubMed PubMed Citation Articles by Sehn, L. H. Articles by Soiffer, R. J. Social Bookmarking                            What's this?

Comparative Outcomes of T-Cell–Depleted and Non–T-Cell–Depleted Allogeneic Bone Marrow Transplantation for Chronic Myelogenous Leukemia: Impact of Donor Lymphocyte Infusion

From the Divisions of Hematologic Malignancies and Biostatistics, Dana-Farber Cancer Institute; and Division of Hematology-Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

Address reprint requests to Dr. Robert J. Soiffer, Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115; email robert_soiffer{at}dfci.harvard.edu

PURPOSE: Donor lymphocyte infusion (DLI) can restore complete remission in patients with chronic myelogenous leukemia (CML) who have relapsed after T-cell–depleted (TCD) allogeneic bone marrow transplantation (BMT). The existence of salvage treatment for patients with DLI after TCD allogeneic BMT prompted an evaluation of overall outcome after CD6⁺-TCD allogeneic BMT for patients treated during the time when DLI has been available.

PATIENTS AND METHODS: We performed a retrospective analysis of outcomes of 46 patients who underwent TCD allogeneic BMT for stable-phase CML and compared these outcomes with those of 40 patients who underwent non-TCD allogeneic BMT. All subjects were patients at one of two neighboring institutions during a period when DLI was available. All patients received marrow from HLA-identical sibling donors, underwent similar myeloablative regimens, and had similar pretreatment characteristics.

RESULTS: After BMT, the TCD group had a lower incidence of grade 2 to 4 acute (15% v 37%, P = .026) and chronic graft-versus-host disease (GVHD) (18% v 42%, P = .024) than did the non-TCD group. The 1-year treatment-related mortality rates for the TCD group and the non-TCD group were 13% and 29%, respectively (P = .07). The estimated 3-year probability of relapse (cytogenetic or hematologic) was higher for patients in the TCD group than for patients in the non-TCD group (62% v 24%, P = .0003). Twenty-three patients (20 in the TCD group and three in the non-TCD group) received and were assessable for response to DLI. After DLI, 17 of 20 patients in the TCD group and two of three patients in the non-TCD group achieved complete remission. Donor lymphocyte infusion induced GVHD in nine of 23 patients. Thirty (65%) of 46 patients in the TCD group and 27 (69%) of 39 assessable patients in the non-TCD group remained alive without evidence of disease. The estimated 3-year overall survival rates were similar for the TCD group and the non-TCD group (72% v 68%, respectively; P = .38). At last follow-up, there was no difference in the overall prevalence of GVHD or the proportion of patients requiring immunosuppressive agents between groups.

CONCLUSION: These results suggest that the combination of T-cell depletion and post-BMT DLI is a viable treatment option for patients undergoing allogeneic BMT for CML and should be prospectively compared with traditional forms of GVHD prophylaxis.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. K. Saifullah, D. A. Fox, S. Sarkar, S. M. A. Abidi, J. Endres, J. Piktel, T. M. Haqqi, and N. G. Singer Expression and Characterization of a Novel CD6 Ligand in Cells Derived from Joint and Epithelial Tissues J. Immunol., November 15, 2004; 173(10): 6125 - 6133. [Abstract] [Full Text] [PDF]

				S. S. Grewal, J. N. Barker, S. M. Davies, and J. E. Wagner Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood? Blood, June 1, 2003; 101(11): 4233 - 4244. [Full Text] [PDF]

				P. Lang, R. Handgretinger, D. Niethammer, P. G. Schlegel, M. Schumm, J. Greil, P. Bader, C. Engel, H. Scheel-Walter, M. Eyrich, et al. Transplantation of highly purified CD34+ progenitor cells from unrelated donors in pediatric leukemia Blood, February 15, 2003; 101(4): 1630 - 1636. [Abstract] [Full Text] [PDF]

				A. H. Elmaagacli, R. Peceny, N. Steckel, R. Trenschel, H. Ottinger, H. Grosse-Wilde, U. W. Schaefer, and D. W. Beelen Outcome of transplantation of highly purified peripheral blood CD34+ cells with T-cell add-back compared with unmanipulated bone marrow or peripheral blood stem cells from HLA-identical sibling donors in patients with first chronic phase chronic myeloid leukemia Blood, January 15, 2003; 101(2): 446 - 453. [Abstract] [Full Text] [PDF]

				S. J. Lee, D. Zahrieh, E. P. Alyea, E. Weller, V. T. Ho, J. H. Antin, and R. J. Soiffer Comparison of T-cell-depleted and non-T-cell-depleted unrelated donor transplantation for hematologic diseases: clinical outcomes, quality of life, and costs Blood, September 26, 2002; 100(8): 2697 - 2702. [Abstract] [Full Text] [PDF]

				F. Dazzi, R. M. Szydlo, J. F. Apperley, and J. M. Goldman Prognostic factors for acute graft-versus-host disease after donor lymphocyte infusions Blood, September 18, 2002; 100(7): 2673 - 2673. [Full Text] [PDF]

				E. Zorn, K. S. Wang, E. P. Hochberg, C. Canning, E. P. Alyea, R. J. Soiffer, and J. Ritz Infusion of CD4+ Donor Lymphocytes Induces the Expansion of CD8+ Donor T Cells with Cytolytic Activity Directed against Recipient Hematopoietic Cells Clin. Cancer Res., July 1, 2002; 8(7): 2052 - 2060. [Abstract] [Full Text] [PDF]

				V. T. Ho and R. J. Soiffer The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation Blood, December 1, 2001; 98(12): 3192 - 3204. [Full Text] [PDF]

				E. Alyea, E. Weller, R. Schlossman, C. Canning, I. Webb, D. Doss, P. Mauch, K. Marcus, D. Fisher, A. Freeman, et al. T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect Blood, August 15, 2001; 98(4): 934 - 939. [Abstract] [Full Text] [PDF]

				X.-F. Yang, C. J. Wu, S. McLaughlin, A. Chillemi, K. S. Wang, C. Canning, E. P. Alyea, P. Kantoff, R. J. Soiffer, G. Dranoff, et al. CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia PNAS, June 19, 2001; 98(13): 7492 - 7497. [Abstract] [Full Text] [PDF]

				B. R. Blazar, C. J. Lees, P. J. Martin, R. J. Noelle, B. Kwon, W. Murphy, and P. A. Taylor Host T Cells Resist Graft-Versus-Host Disease Mediated by Donor Leukocyte Infusions J. Immunol., November 1, 2000; 165(9): 4901 - 4909. [Abstract] [Full Text] [PDF]

				A. E. Searles, S. J. Pohlmann, L. J. Pierce, S. S. Perry, W. B. Slayton, M. P. Mojica, and G. J. Spangrude Rapid, B Lymphoid-Restricted Engraftment Mediated by a Primitive Bone Marrow Subpopulation J. Immunol., July 1, 2000; 165(1): 67 - 74. [Abstract] [Full Text] [PDF]

				C. Craddock, R. M. Szydlo, J. P. Klein, F. Dazzi, E. Olavarria, F. van Rhee, C. Pocock, K. Cwynarski, J. F. Apperley, and J. M. Goldman Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission Blood, July 1, 2000; 96(1): 86 - 90. [Abstract] [Full Text] [PDF]

				C. Guglielmi, W. Arcese, J. Hermans, A. Bacigalupo, G. Bandini, D. Bunjes, E. Carreras, A. Devergie, F. Frassoni, J. Goldman, et al. Risk assessment in patients with Ph+ chronic myelogenous leukemia at first relapse after allogeneic stem cell transplant: an EBMT retrospective analysis Blood, June 1, 2000; 95(11): 3328 - 3334. [Abstract] [Full Text] [PDF]